FDA Warning Letter Targets Erectin Stimulating Gel and VigRX Delay Wipes
FDA issued a warning letter to Leading Edge Health Inc. after reviewing the company’s website and determining that two sexual health products were being marketed as unapproved new drugs.
The products identified were “Erectin Stimulating Gel” and “VigRX Delay Wipes.” FDA cited website claims such as “INSTANT ERECTION formula,” “Rock Hard Erections,” and “Longer-Lasting Erections” as evidence that the products were intended to affect the structure or function of the body.
FDA also cited claims for VigRX Delay Wipes related to premature ejaculation, including references to numbing effects and blood circulation.
Because the products were marketed with drug-like claims but did not have FDA-approved applications, FDA concluded they were unapproved new drugs under the Federal Food, Drug, and Cosmetic Act.
The warning letter directed the firm to respond within 15 business days with corrective actions and measures to prevent recurrence.
MDP Perspective
This warning letter is a useful reminder that product classification is driven by intended use, not by how a company wishes to position a product. Website language, product names, promotional claims, and implied benefits can all create drug status.
For companies marketing sexual health, wellness, or performance products, aggressive claims can quickly move a product from cosmetic or supplement positioning into drug territory. Once that happens, FDA expects an approved drug application or a clear legal marketing pathway.
Links
Warning letter to Leading Edge Health, Inc.
Warning Letter to Wild Arabic Herbs
FDA Issues 14 Warning Letters Targeting Online Unapproved Drug Sales
The Regulatory Dilemma of Experimental Peptides
As demand for experimental peptides grows, a fundamental question confronts federal regulators. Can access to unapproved drug products expand without compromising the standards intended to protect patients? The growing popularity of experimental peptides such as...
FDA Moves Toward New Peptide Compounding Policy
FDA Moves Toward New Peptide Compounding PolicyAgency submits proposed policy change for White House review as HHS signals support for expanded access to experimental peptides Nearly three months after an FDA advisory committee recommended adding six experimental...
Pharmacal Recalls MG217 Eczema Cream
Pharmacal Recalls MG217 Eczema Cream Due to Staphylococcus aureus ContaminationFDA posts nationwide recall after microbial contamination found in topical skin treatment Pharmacal has voluntarily recalled one lot of MG217 Multi-Symptom Treatment Cream & Skin...
Cefazolin Injection Recalled Due to Cardboard in Sterile IV Solution
Baxter Recalls Cefazolin Injection Sterile IV SolutionCardboard Particulate Matter Found in a Sterile Intravenous Infusion Bag Baxter International has voluntarily recalled one lot of Cefazolin in Dextrose Injection, USP, 2 g/100 mL after a report of cardboard...
FDA Early Alert for Baxter Intravascular Administration Sets
Healthcare facilities are instructed to immediately stop using affected IV solution sets while FDA evaluates the potentially high-risk device issueThe U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding certain Baxter Duo-Vent Solution Sets...
Why the Sudden Focus on Testosterone?
New Military Screening Program Raises Questions About Science, Strategy and TransparencyThe Trump administration's decision to begin annual testosterone screening for active-duty and reserve service members age 30 and older has generated headlines and a growing number...
